Circulating microRNA as Biomarkers: An update in prostate cancer

Molecular and Cellular Pharmacology

Volumn 3, Issue 3, 2011, Pages 115-124

  Srivastava, Anvesha ^a   Suy, Simeng ^b,c   Collins, Sean P ^b,c   Kumar, Deepak ^a,b  

^a UNIVERSITY OF THE DISTRICT OF COLUMBIA   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Biomarker; Cancer; Circulating miRNA; miRNA; Prostate

Indexed keywords

BIOLOGICAL MARKER; CIRCULATING MICRORNA; LET 7; MICRORNA; MIR 122; MIR 195; MIR 208; MIR 34; MIR 499; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER DIAGNOSIS; CANCER GENE THERAPY; CANCER INHIBITION; CARCINOGENESIS; DIGITAL RECTAL EXAMINATION; DRUG SCREENING; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GENETIC REGULATION; HEART FAILURE; HEART INFARCTION; HEPATITIS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; NONHUMAN; PROSTATE CANCER; PROSTATE TUMOR;

EID: 84855463130     PISSN: None     EISSN: 19381247     Source Type: Journal    
DOI: 10.4255/mcpharmacol.11.16     Document Type: Article

References (95)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Nelen V. Epidemiology of Prostate Cancer. In: Ramon J, Denis LJ, editors. Prostate Cancer, Berlin Heidelberg: Springer; 2007. p. 1-8.
3. Blute ML. No proof of inferiority: open radical retropubic prostatectomy remains state-of-the-art surgical technique for localized prostate cancer. J Urol 2009;181:2421-3.
4. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152:1850-7.
5. Zincke H, Bergstralh EJ, Blute ML et al. Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution. J Clin Oncol 1994;12:2254-63.
6. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol 1998;160:2428-34.
7. Carvalhal GF, Griffin CR, Kan D, Loeb S, Catalona WJ. Reducing blood loss in open radical retropubic prostatectomy with prophylactic periprostatic sutures. BJU Int 2010;105:1650-3.
8. Swanson GP, Riggs MW, Earle JD, Haddock MG. Long-term follow-up of radical retropubic prostatectomy for prostate cancer. Eur Urol 2002;42:212-16.
9. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008;8:268-78.
10. Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.
11. Backer H. Prostate cancer screening: exploring the debate. Permanente J 1999;3:330-40.
12. Schröder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized european study. N Engl J Med 2009;360:1320-8.
13. Andriole GL, Grubb RL, Buys SS et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-19.
14. Djulbegovic M, Beyth RJ, Neuberger MM et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010;341:c4543.
15. Jansen FH, van Schaik RHN, Kurstjens J et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010;57:921-7.
16. Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A. Tumor markers in prostate cancer I: Blood- based markers. Acta Oncol 2011;50:61-75.
17. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-233.
18. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
19. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC, Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urol 2011;77:1265 e1269.
20. Esquela-Kerscher A, Slack FJ. Oncomirs [mdash] microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
21. Brase JC, Wuttig D, Kuner R, Sultmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 2010;9:306.
22. Stefani G, Slack FJ. Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol 2008;9:219-30.
23. Houbaviy HB, Murray MF, Sharp PA. Embryonic stem cell-specific microRNAs. Dev Cell 2003;5:351-8.
24. Li C, Feng Y, Coukos G, Zhang L. Therapeutic microRNA strategies in human cancer. AAPS J 2009;11:747-57.
25. Hoefig KP, Heissmeyer V. MicroRNAs grow up in the immune system. Curr Opin Immunol 2008;20:281-7.
26. Bonci D, Coppola V, Musumeci M et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008;14:1271-7.
27. Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002;99:15524-9.
28. Ribas J, Ni X, Haffner M et al. Mir-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 2009;69:7165-69.
29. Selaru FM, Olaru AV, Kan T et al. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 2009;49:1595-1601.
30. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007;133:647-58.
31. Eis PS, Tam W, Sun L et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A 2005;102:3627-32.
32. Gironella M, Seux M, Xie M-J et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A 2007;104:16170-5.
33. Gregory PA, Bert AG, Paterson EL et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008;10:593-601.
34. Meng F, Henson R, Lang M et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006;130:2113-29.
35. Iorio MV, Visone R, Di Leva G et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007;67:8699-8707.
36. Camps C, Buffa FM, Colella S et al. Hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in Bbreast cancer. Clinical Cancer Res 2008;14:1340-8.
37. Mathew LK, Simon MC. Mir-210: A sensor for hypoxic stress during tumorigenesis. Mol Cell 2009;35:737-8.
38. Volinia S, Calin GA, Liu CG et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257-61.
39. Lawrie CH, Gal S, Dunlop HM et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008;141:672-5.
40. Yu DC, Li QG, Ding XW, Ding YT. Circulating microRNAs: potential biomarkers for cancer. Int J Mol Sci 2011;12:2055-63.
41. Dbouk HA, Tawil A, Nasr F, Kandakarjian L, Abou-Merhi R. Significance of CEA and VEGF as diagnostic markers of colorectal cancer in Lebanese patients. Open Clin Cancer J 2007;1:1-5.
42. Schneider J, Velcovsky HG, Morr H, Katz N, Neu K, Eigenbrodt E. Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer. Anticancer Res 2000;20:5053-8.
43. Huber K, Kirchheimer JC, Ermler D, Bell C, Binder BR. Determination of plasma urokinase-type plasminogen activator antigen in patients with primary liver cancer: characterization as tumor-associated antigen and comparison with alpha-fetoprotein. Cancer Res 1992;52:1717-20.
44. Stenman UH, Paus E, Allard WJ et al. Summary report of the TD-3 workshop: characterization of 83 antibodies against prostate-specific antigen. Tumour Biol 1999;20 Suppl 1:1-12.
45. Fleischhacker M, Schmidt B. Free circulating nucleic acids in plasma and serum (CNAPS) -- Useful for the detection of lung cancer patients? Cancer Biomark 2010;6:211-19.
46. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977;37:646-50.
47. Vlassov VV, Laktionov PP, Rykova EY. Circulating nucleic acids as a potential source for cancer biomarkers. Curr Mol Med 2010;10:142-65.
48. Tong YK, Lo YM. Diagnostic developments involving cell-free (circulating) nucleic acids. Clin Chim Acta 2006;363:187-96.
49. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513-18.
50. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.
51. Kosaka N, Izumi H, Sekine K, Ochiya T. microRNA as a new immune-regulatory agent in breast milk. Silence 2010;1:7.
52. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011;39:7223-33.
53. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Developmental Biology 2007;302:1-12.
54. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8.
55. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
56. Nana-Sinkam SP, Croce CM. MicroRNAs as therapeutic targets in cancer. Transl Res 2011;157:216-225.
57. Barker EV, Cervigne NK, Reis PP et al. Microrna evaluation of unknown primary lesions in the head and neck. Mol Cancer 2009;8:127.
58. Lawrie CH, Gal S, Dunlop HM et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008;141:672-5.
59. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast Cancer. Ann Surg 2010;251:499-505.
60. Hu Z, Chen X, Zhao Y et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010;28:1721-6.
61. Heegaard NHH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, Harris CC. Circulating microRNA expression profiles in early stage non-small cell lung cancer. Int J Cancer 2011 [Epub ahead of print]
62. Olson P, Lu J, Zhang H et al. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes & Dev 2009;23:2152-65.
63. Li A, Omura N, Hong S-M et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res 2010;70:5226-37.
64. Wang J, Chen J, Chang P et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res 2009;2:807-13.
65. Ho AS, Huang X, Cao H et al. Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol 2010;3:109-13.
66. Wong T-S, Liu X-B, Wong BY-H, Ng RW-M, Yuen AP-W, Wei WI. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res 2008;14:2588-92.
67. Wang F, Zheng Z, Guo J, Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol 2010;119:586-93.
68. Tsujiura M, Ichikawa D, Komatsu S et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010;102:1174-9.
69. Liu R, Zhang C, Hu Z et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 2011;47:784-91.
70. Zhu W, Qin W, Atasoy U, Sauter E. Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes 2009;2:89.
71. Shigoka M, Tsuchida A, Matsudo T et al. Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol Int 2010;60:351-7.
72. Yamamoto Y, Kosaka N, Tanaka M et al. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers 2009;14:529-38.
73. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010;127:118-26.
74. Ng EKO, Chong WWS, Jin H et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009;58:1375-81.
75. Tanaka M, Oikawa K, Takanashi M et al. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One 2009;4:e5532.
76. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009;112:55-9.
77. Hausler SFM, Keller A, Chandran PA et al. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer 2010;103:693-700.
78. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecologic Oncol 2008;110:13-21.
79. Weber JA, Baxter DH, Zhang S et al. The MicroRNA Spectrum in 12 Body Fluids. Clin Chem 2010;56:1733-41.
80. Liu CJ, Kao SY, Tu HF, Tsai MM, Chang KW, Lin SC. Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis 2010;16:360-4.
81. Park NJ, Zhou H, Elashoff D et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 2009;15:5473-7.
82. Yamada Y, Enokida H, Kojima S et al. MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci 2011;102:522-9.
83. Chan E, Prado DE, Weidhaas JB. Cancer microRNAs: From subtype profiling to predictors of response to therapy. Trends Mol Med 2011;17:235-43.
84. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TLJ, Visakorpi T. MicroRNA Expression Profiling in Prostate Cancer. Cancer Res 2007;67:6130-5.
85. Ambs S, Prueitt RL, Yi M et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008;68:6162-70.
86. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513-8.
87. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 2009;4:e6229.
88. Brase JC, Johannes M, Schlomm T et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 2011;128:608-16.
89. Kota J, Chivukula RR, O'Donnell KA et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009;137:1005-17.
90. Takeshita F, Patrawala L, Osaki M et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 2009;18:181-7.
91. Wiggins JF, Ruffino L, Kelnar K et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 2010;70:5923-30.
92. Trang P, Medina PP, Wiggins JF et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010;29:1580-7.
93. Liu C, Kelnar K, Liu B et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011;17:211-5.
94. Mostert B, Sieuwerts AM, Martens JW, Sleijfer S. Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients. Expert Rev Mol Diagn 2011;11:259-75.
95. Moltzahn F, Olshen AB, Baehner L et al. Microfluidic- based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 2011;71:550-60.